FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROSE ERIC A MD					2. Issuer Name and Ticker or Trading Symbol SIGA TECHNOLOGIES INC [SIGA]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O SIGA TECHNOLOGIES, INC. 420 LEXINGTON AVENUE, SUITE 408					3. Date of Earliest Transaction (Month/Day/Year) 11/14/2008								X	Officer (sixe title Other (specify				
(Street) NEW YORK NY 10170 (City) (State) (Zip)				4.									i. Indiv ine) X	′				
1. Title of Security (Instr. 3) 2. Trans. Date				Transaction te	·			3. Transac Code (li	ransaction Disposed Of (D) (Instr. 3, 4 ode (Instr.			ed (A) or	r 5. Amount o and 5) Securities Beneficially Owned Follo		Form: y (D) or		r Indirect E str. 4)	7. Nature of ndirect Beneficial Ownership
								Code	v	Amount	(A) o	(A) or (D) Prio		Reported Transaction (Instr. 3 au	ion(s)			Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)			and 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	Date Expiration Date Title Amount or Number of Shares			(Instr. 4)								
Stock Option (Right to buy)	\$2.49	11/14/2008		A		400,000		(1)	11	1/14/2018	Common Stock, par value \$.0001 per share	400,0	00	\$0	1,020,000) ⁽²⁾	D	

Explanation of Responses:

- 1. The options with respect to 100,000 shares will vest pro rata on the first, second and third anniversaries of the date of grant. The options with respect to the remaining 300,000 shares will vest upon achievement of certain milestones.
- 2. Includes 1,020,000 shares of common stock issuable upon exercise of options. Does not include shares of common stock that Dr. Rose, as a director of TransTech Pharma, may be deemed to beneficially own and as to which Dr. Rose disclaims beneficial ownership.

Remarks:

/s/ Eric A. Rose

11/17/2008

** Signature of Reporting Person

Doto

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.